| |
| |
|
| Insider
Information: |
Worland Stephen T |
| Relationship: |
Chief Executive Office... |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
367,620 |
|
|
Indirect Shares
|
771,043 |
|
|
| Direct
Value |
$497,115 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
1,138,663 |
|
|
| Total
Value |
$497,115 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Anadys Pharmaceuticals Inc |
ANDS |
President and CEO, Dir... |
2008-05-30 |
72,317 |
2008-05-30 |
208,704 |
Premium* |
|
|
Genmark Diagnostics, Inc. |
GNMK |
Director |
2014-05-29 |
20,599 |
2013-05-22 |
0 |
Premium* |
|
|
Tracon Pharmaceuticals, Inc. |
TCON |
Director |
2016-06-01 |
7,500 |
2016-06-01 |
0 |
Premium* |
|
|
Effector Therapeutics Ord Shs |
EFTR |
Chief Executive Office... |
2023-11-15 |
267,204 |
2023-11-15 |
562,339 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
21 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| EFTR |
Effector Therapeutics Ord... |
Chief Executive Officer |
• • – |
2023-11-15 |
4 |
A |
$0.50 |
$2,973 |
D/D |
5,979 |
267,204 |
0 |
- |
|
| EFTR |
Effector Therapeutics Ord... |
Chief Executive Officer |
• • – |
2023-08-11 |
4 |
OE |
$0.52 |
$17,575 |
D/D |
33,799 |
261,225 |
0 |
- |
|
| EFTR |
Effector Therapeutics Ord... |
Chief Executive Officer |
• • – |
2023-05-15 |
4 |
A |
$0.46 |
$2,938 |
D/D |
6,401 |
227,426 |
0 |
- |
|
| EFTR |
Effector Therapeutics Ord... |
Chief Executive Officer |
• • – |
2022-11-15 |
4 |
A |
$0.47 |
$2,832 |
D/D |
6,047 |
221,025 |
0 |
- |
|
| EFTR |
Effector Therapeutics Ord... |
President and Chief Executive |
• • – |
2022-05-13 |
4 |
A |
$1.53 |
$2,811 |
D/D |
1,837 |
194,978 |
0 |
- |
|
| EFTR |
Effector Therapeutics Ord... |
President and Chief Executive |
• • – |
2021-08-25 |
4 |
A |
$0.00 |
$500,000 |
I/I |
562,339 |
562,339 |
0 |
- |
|
| EFTR |
Effector Therapeutics Ord... |
President and Chief Executive |
• • – |
2021-08-25 |
4 |
A |
$0.00 |
$0 |
D/D |
193,141 |
755,480 |
0 |
- |
|
| TCON |
Tracon Pharmaceuticals, I... |
Director |
– • – |
2016-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
7,500 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
Director |
– • – |
2014-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
5,677 |
20,599 |
0 |
- |
|
| GNMK |
Genmark Diagnostics, Inc. |
Director |
– • – |
2013-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
14,922 |
14,922 |
0 |
- |
|
| ANDS |
Anadys Pharmaceuticals In... |
President and CEO |
• • – |
2008-05-30 |
4 |
OE |
$2.95 |
$99,999 |
D/D |
33,898 |
72,317 |
0 |
- |
|
| ANDS |
Anadys Pharmaceuticals In... |
President and CEO |
• • – |
2007-09-04 |
4 |
B |
$2.34 |
$31,096 |
I/I |
13,236 |
208,704 |
2.66 |
- |
|
| ANDS |
Anadys Pharmaceuticals In... |
President and CEO |
• • – |
2007-08-31 |
4 |
B |
$2.08 |
$25,714 |
I/I |
12,200 |
195,468 |
2.66 |
- |
|
| ANDS |
Anadys Pharmaceuticals In... |
President and CEO |
• • – |
2007-08-30 |
4 |
B |
$2.00 |
$249,128 |
I/I |
124,564 |
183,268 |
2.66 |
- |
|
| ANDS |
Anadys Pharmaceuticals In... |
President and CEO |
• • – |
2007-01-12 |
4/A |
OE |
$2.95 |
$73,750 |
D/D |
25,000 |
28,557 |
0 |
- |
|
| ANDS |
Anadys Pharmaceuticals In... |
President, Pharmaceuticals |
• – – |
2007-01-12 |
4 |
OE |
$2.95 |
$73,750 |
D/D |
25,000 |
27,586 |
0 |
- |
|
| ANDS |
Anadys Pharmaceuticals In... |
EVP, Pharmaceuticals |
• – – |
2006-03-16 |
4 |
AS |
$16.00 |
$64,000 |
I/I |
(4,000) |
58,704 |
|
- |
|
| ANDS |
Anadys Pharmaceuticals In... |
EVP, Pharmaceuticals |
• – – |
2006-03-02 |
4 |
S |
$14.00 |
$42,000 |
I/I |
(3,000) |
63,083 |
|
- |
|
| ANDS |
Anadys Pharmaceuticals In... |
EVP, Pharmaceuticals |
• – – |
2006-03-02 |
4/A |
AS |
$14.00 |
$42,000 |
I/I |
(3,000) |
62,704 |
|
- |
|
| ANDS |
Anadys Pharmaceuticals In... |
EVP, Research and Development |
• – – |
2005-05-31 |
4 |
OE |
$2.95 |
$74,930 |
D/D |
25,400 |
26,352 |
|
- |
|
| ANDS |
Anadys Pharmaceuticals In... |
Chief Scientific OfficerOffice |
• – – |
2004-03-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
39,352 |
|
- |
|
21 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
